You are here

Article info

Article menu
Download PDFPDF
Letters
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis

Authors

  1. Correspondence to Professor Markku Hakala, Division of Rheumatology, Department of Medicine, Päijät-Häme Central Hospital, Keskussairaalankatu 7, Lahti 15850, Finland; markku.hakala{at}fimnet.fi
View Full Text

Citation

Hakala M, Immonen K, Korpela M, et al
Good medium-term efficacy of tocilizumab in DMARD and anti-TNF-α therapy resistant reactive amyloidosis
Annals of the Rheumatic Diseases 2013;72:464-465.

Publication history

  • Accepted October 20, 2012
  • First published November 12, 2012.
Online issue publication 
April 13, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions